Hormone replacement therapy in postmenopausal women with end-stage renal disease1  by Andreoli, Sharon P.
Kidney International, Vol. 57 (2000), pp. 341–342
EDITORIAL
Hormone replacement therapy in postmenopausal women with
end-stage renal disease1
Since the life expectancy of women has increased sub- placement therapy may have a higher risk of thrombosis
of vascular access.stantially over the past several decades, women are living
a larger portion of their lives following menopause and Use of hormone replacement therapy in the general
population of postmenopausal women varies consider-in a state of estrogen deficiency. Following menopause,
the risk of coronary artery disease increases substantially ably based on the demographics of the study population,
but some population-based studies demonstrate thatand estrogen deficiency contributes to the develop-
about one fourth to one third of postmenopausal womenment of osteoporosis and hip fractures in older women
receive hormone replacement therapy [10, 11]. Recent[1, 2]. Hormone replacement therapy with estrogen com-
studies using USRDS data have demonstrated that ap-pounds has been shown to alleviate the symptoms of
proximately 10% of women with ESRD are treated withmenopause, decrease the incidence of coronary artery
hormone replacement therapy [12]. Stehman-Breen, Gil-disease and hip fractures, improve the lipid profile, retard
len, and Gipson also document that about 10% of womenor prevent the development of osteoporosis, and possibly
with ESRD receive hormone replacement therapy, andpreserve cognitive function and prevent the development
they report for the first time the clinical characteristicsof dementia [1–5]. The adverse effects of hormone re-
associated with use of hormone replacement therapy inplacement therapy include an increased incidence of en-
women with ESRD [11]. Using USRDS data, Stehman-dometrial hyperplasia that can be nearly eliminated by
Breen, Gillen, and Gipson found that postmenopausalthe administration of progesterone in addition to estro-
women with ESRD were more likely to be white, ambu-gen [1]. While the increased risk of endometrial hyper-
latory, have a college education, and were more likelyplasia and endometrial cancer in postmenopausal women
to be younger. In addition, women with ESRD receivingreceiving hormone replacement therapy is established,
hormone replacement therapy were more likely to beit remains unclear if postmenopausal women receiving
maintained by peritoneal dialysis and to not be diabetic.hormone replacement therapy have a higher risk of
It is remarkable that the use of hormone replacementbreast cancer, and the risk of this side effect of hormone
therapy in women with ESRD who are at higher riskreplacement therapy remains controversial [5, 6]. Hor-
for cardiovascular disease, bone disease, and cognitivemone replacement therapy is also associated with a
impairment is only 10%. Thus, women with ESRD whohigher incidence of thromboembolism [7].
might substantially benefit from hormone replacementPatients with end-stage renal disease (ESRD) are at
therapy are significantly undertreated compared to therisk for the development of renal osteodystrophy and
general population. Given the substantial protectionthey have a higher risk for accelerated atherosclerosis
from cardiovascular disease that hormone replacementand cardiovascular disease compared to people in the
therapy provides in postmenopausal women, physiciansgeneral population [8, 9]. Thus, the adverse effects of est-
caring for such women should ask why women withrogen deficiency may be particularly evident in women
ESRD are significantly undertreated compared to thewith ESRD and women with ESRD may potentially
general population? Is it because they are perceived asbenefit from hormone replacement therapy. Conversely,
unlikely to benefit from such therapy due to chronicwomen with ESRD may also have a higher incidence of
illness and a potentially shortened life expectancy? Is itadverse effects of hormone replacement therapy, includ-
because women with ESRD might have a higher risk ofing an increased incidence of cancer due to possible
endometrial hyperplasia and the potential risk of breastabnormalities in immune surveillance from chronic ure-
cancer compared to the general population, or is it be-mia and/or women with ESRD receiving hormone re-
cause such therapy may increase the risk of thromboem-
bolism and clotting of vascular access? The answers to
1 This editorial was submitted to accompany the article by Stehman- these and other questions are unknown, but such infor-
Breen, Gillen, and Gipson [11]. The Editors regret the omission. mation will be important to obtain so that physicians
caring for women with ESRD and women with ESRDKey words: estrogen, coronary artery disease, ESRD, osteoporosis,
atherosclerosis. understand the benefits and risks of hormone replace-
ment therapy. 2000 by the International Society of Nephrology
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Stehman-Breen, Gillen, and Gipson found that women man-Breen, Gillen, and Gipson [11] are to be encour-
with ESRD who were ambulatory were twice as likely aged, so that women with ESRD can make an educated
and women with a college education were three times decision about hormone replacement therapy.
as likely to receive hormone replacement therapy, while
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replacement therapy in women with ESRD as com-
pared to the general population. However, as pointed out
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